JP2002348254A - 神経系腫瘍治療剤 - Google Patents

神経系腫瘍治療剤

Info

Publication number
JP2002348254A
JP2002348254A JP2001155237A JP2001155237A JP2002348254A JP 2002348254 A JP2002348254 A JP 2002348254A JP 2001155237 A JP2001155237 A JP 2001155237A JP 2001155237 A JP2001155237 A JP 2001155237A JP 2002348254 A JP2002348254 A JP 2002348254A
Authority
JP
Japan
Prior art keywords
protein
cells
hub
bcl
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001155237A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002348254A5 (enExample
Inventor
Yoshiyuki Okano
栄之 岡野
Wado Akamatsu
和土 赤松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Science and Technology Agency
Original Assignee
Japan Science and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Science and Technology Corp filed Critical Japan Science and Technology Corp
Priority to JP2001155237A priority Critical patent/JP2002348254A/ja
Priority to US10/478,514 priority patent/US20040147438A1/en
Priority to CA002446510A priority patent/CA2446510A1/en
Priority to PCT/JP2001/008701 priority patent/WO2002094306A1/ja
Publication of JP2002348254A publication Critical patent/JP2002348254A/ja
Publication of JP2002348254A5 publication Critical patent/JP2002348254A5/ja
Priority to US11/771,083 priority patent/US20070299031A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2001155237A 2001-05-24 2001-05-24 神経系腫瘍治療剤 Pending JP2002348254A (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2001155237A JP2002348254A (ja) 2001-05-24 2001-05-24 神経系腫瘍治療剤
US10/478,514 US20040147438A1 (en) 2001-05-24 2001-10-03 Remedies for nervous tumor
CA002446510A CA2446510A1 (en) 2001-05-24 2001-10-03 Therapeutic agent for tumor of neural origin
PCT/JP2001/008701 WO2002094306A1 (fr) 2001-05-24 2001-10-03 Remedes pour le traitement des tumeurs nerveuses
US11/771,083 US20070299031A1 (en) 2001-05-24 2007-06-29 Therapeutic agent for tumor of neural origin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001155237A JP2002348254A (ja) 2001-05-24 2001-05-24 神経系腫瘍治療剤

Publications (2)

Publication Number Publication Date
JP2002348254A true JP2002348254A (ja) 2002-12-04
JP2002348254A5 JP2002348254A5 (enExample) 2005-09-08

Family

ID=18999466

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001155237A Pending JP2002348254A (ja) 2001-05-24 2001-05-24 神経系腫瘍治療剤

Country Status (4)

Country Link
US (2) US20040147438A1 (enExample)
JP (1) JP2002348254A (enExample)
CA (1) CA2446510A1 (enExample)
WO (1) WO2002094306A1 (enExample)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036142A2 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
KR20060031809A (ko) * 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법

Also Published As

Publication number Publication date
CA2446510A1 (en) 2002-11-28
WO2002094306A1 (fr) 2002-11-28
US20070299031A1 (en) 2007-12-27
US20040147438A1 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
EP2114153B1 (en) Treatment and prevention of neurodegenerative diseases using gene therapy
JPH09507747A (ja) 中枢神経系の幹細胞の原位置修飾及び操作
CN102389413A (zh) 用于治疗糖尿病的组合物及其应用
US8329654B2 (en) Use of IL-6/IL-6 chimera in Huntington's disease
Chen et al. Co-transduction of dual-adeno-associated virus vectors in the neonatal and adult mouse utricles
AU749530B2 (en) CNS neuroregenerative compositions and methods of use
Koyama et al. Endothelins stimulate the expression of neurotrophin-3 in rat brain and rat cultured astrocytes
US20240247055A1 (en) Inhibition of Tau Propagation
CN108392492A (zh) Ldlr过表达在nk细胞过继治疗中的应用
CN116675779B (zh) 一种靶向Src激酶的短肽及其在系统性真菌感染中的应用
JP2002348254A (ja) 神経系腫瘍治療剤
CA2340596A1 (en) Guanylate binding protein (gbp-1) as inhibitor of cell proliferation and molecular marker for the determination of the stage of cellular differentiation
KR101607629B1 (ko) miRNA를 이용한 C형 간염 바이러스 감염 질환의 예방 또는 치료
US20210379144A1 (en) Homeoproteins for use in the treatment of neurodegenerative disorders
JP2020527132A (ja) ミエリン障害を治療するための組成物および方法
Rubin et al. Potential for promoting recurrent laryngeal nerve regeneration by remote delivery of viral gene therapy
AU2001291849A1 (en) Use of IL-6R/IL-6 chimera in Huntington's disease
US10052362B2 (en) Glial cell line derived neurotrophic factor, obesity, and obesity-related diseases and conditions
CN100556455C (zh) 一种用于预防和治疗i型糖尿病的药物复合物及其应用
US20030121064A1 (en) CNS neuroregenerative compositions and methods of use
US20220041673A1 (en) Method and kit for treating a neurodegenerative disease
KR20250047689A (ko) 알파-시누클레인 응집 억제용 조성물 및 응집억제 방법
Ganglion INHERITED, AQUIRED AND PROGRESSIVE NEUROLOGICAL DISEASES
JP2001524812A (ja) アポトーシス誘導タンパク質に対するｒｂの比率の減少による悪性細胞におけるアポトーシス細胞死の誘導方法
NZ749459A (en) TATĸ-CDKL5 FUSION PROTEINS, COMPOSITIONS, FORMULATIONS, AND USE THEREOF

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20040210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080821

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081118